Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a decline of 2.77% in the biopharmaceutical sector, while the total A-share market fell by 3.42% [1][35] - Cardiovascular diseases remain the leading cause of death globally, with significant advancements in drug development targeting inflammation pathways, particularly NLRP3, IL-1, and IL-6 [2][33] - The report highlights the importance of addressing "residual risk" in cardiovascular treatment beyond traditional lipid-lowering therapies [33] Summary by Sections Market Performance - The overall A-share market declined by 3.42%, with the Shanghai Composite Index down 2.19% and the ChiNext Index up 1.26% [1][35] - The biopharmaceutical sector's price-to-earnings (P/E) ratio stands at 35.19x, which is at the 77.27th percentile of its historical valuation over the past five years [1][40] Drug Development Insights - The first tier of drug development focuses on apoB/LDL-C, with established treatment paradigms including statins and PCSK9 inhibitors [2][15] - The second tier involves Lp(a) and its associated genetic risks, with several candidates in late-stage clinical trials [2][15] - The third tier emphasizes the NLRP3→IL-1→IL-6→CRP pathway, which is gaining recognition for its clinical relevance in cardiovascular disease [2][33] Company Earnings Forecasts and Ratings - Major companies in the sector, such as Mindray Medical (P/E 17.6x), United Imaging (P/E 74.4x), and WuXi AppTec (P/E 29.2x), are rated as "Outperform" [4] - The report provides detailed earnings forecasts for these companies, indicating expected growth in net profits over the next few years [4] Recommended Stocks - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure and international expansion [44] - WuXi AppTec is noted for its comprehensive service capabilities in drug development, poised to benefit from the global outsourcing market [44] - Other recommended companies include United Imaging, New Industries, and Yuyue Medical, each with unique strengths in their respective fields [44][45]

Summary of Key Points from the Conference Call on China's Silver Economy: Healthcare & Insurance Industry Overview - **Industry Focus**: The report centers on the healthcare and insurance sectors in China, particularly in the context of the aging population and the emerging "Silver Economy" [1][2][12]. Core Insights and Arguments - **Demographic Shift**: China is experiencing a rapid demographic transformation, with the population aged 65 and above expected to exceed 224 million by 2025, accounting for nearly 16% of the total population. This shift is significantly faster than in other major economies [12][13]. - **Healthcare Expenditure Growth**: Non-reimbursable healthcare expenditure is projected to grow from RMB 3.2 trillion in 2025 to RMB 6.5 trillion by 2035, reflecting a CAGR of 7.2%. This growth is driven by increased healthcare spending among older adults and the inadequacy of public healthcare funding [2][22]. - **Commercial Insurance Expansion**: The commercial insurance sector is expected to capture a larger share of healthcare expenditure, potentially covering 18% by 2035, up from 7% in 2024. This shift will add approximately RMB 2 trillion in funding to the healthcare system [28][29]. Key Beneficiaries - **Healthcare Sector**: - **Chronic Disease Management**: Online and offline chronic disease management services are crucial for elderly care delivery [3][40]. - **Innovative Pharma & Biotech**: Companies focusing on age-related disease treatments are positioned for growth, with innovative drug sales expected to grow at a CAGR of 15% by 2035 [4][29]. - **Advanced Medtech**: Firms providing solutions for physiological decline are also set to benefit [3][40]. - **Insurance Sector**: - **Commercial Long-Term Care Insurance (LTCI)**: The rollout of a nationwide LTCI system in 2026 presents significant opportunities for insurers, with premiums expected to grow at a CAGR of 12% from 2024 to 2030 [5][36]. Additional Important Insights - **Funding Gap**: The gap between total healthcare demand and public funding is widening, creating substantial market opportunities for commercial insurers and healthcare providers [21][25]. - **Health Literacy Increase**: The rise in health literacy among the elderly population is expected to drive demand for higher-quality healthcare services and innovative therapies [43]. - **Digital Health Ecosystem**: The integration of AI-driven platforms with traditional healthcare services is reshaping chronic disease management, enhancing patient engagement and care delivery [48][49]. Benefited Stocks - **Insurance Companies**: PICC P&C, China Life, CPIC are identified as key players in the insurance sector [6][36]. - **Healthcare Services**: Companies like Ali Health, Fangzhou, Gushengtang, and Aier Eye Hospital are positioned to benefit from the growing demand for healthcare services [6][40]. - **Pharma/Biotech**: Hengrui, Innovent, and Ribo are highlighted for their focus on innovative treatments for age-related diseases [6][40]. - **MedTech**: MicroPort is noted for its advancements in medical technology relevant to aging populations [6][40]. Conclusion - The aging population in China presents a multi-decade growth opportunity for both the healthcare and insurance sectors. The structural changes in demographics, coupled with increasing health awareness and technological advancements, are set to reshape the landscape of healthcare and insurance in the country [1][12][36].

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6] Core Views - The medical and biological sector experienced a decline of 2.77% this week, ranking 8th among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index fell by 2.19%, indicating that the medical sector underperformed by 0.59 percentage points [1] - The report highlights a new policy from the Ministry of Commerce aimed at promoting international medical tourism, which is expected to enhance the appeal of private hospitals by allowing them to tap into high-value services such as high-end physical examinations and cosmetic surgery [4] - The medical services sector's current Price-to-Earnings (PE) ratio is 30.77X, with a Price-to-Book (PB) ratio of 3.12X, reflecting a slight decrease from the previous week [3] Summary by Sections Industry Performance - The medical services sector index closed at 6472.58 points, down 4.32% for the week, while the overall medical and biological sector index fell by 2.77% [1][22] - Notable performers in the medical services sector included WuXi AppTec (0.0%) and Aier Eye Hospital (-1.8%), while companies like Sanbo Brain Science and Proprius saw significant declines of -20.7% and -16.8%, respectively [2][22] Valuation Metrics - The medical services sector's PE ratio (ttm) is 30.77X, with a one-year maximum of 41.13X and a minimum of 28.46X. The current PB ratio is 3.12X, with a one-year maximum of 4.00X and a minimum of 2.48X [3] Investment Suggestions - The report suggests focusing on high-growth areas such as ADC CDMO and the peptide CDMO in the weight loss drug supply chain, with companies like WuXi AppTec and Aier Eye Hospital recommended for their growth potential [5] - It also highlights the potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [5]

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector, highlighting potential opportunities due to upcoming clinical data and successful overseas clinical progress of pipelines [2][4]. Core Insights - The chemical products sector is experiencing significant price increases due to rising international oil prices and high overseas energy costs, particularly affecting solvent products which are difficult to stockpile [1][10]. - The raw material pharmaceutical products are expected to see price increases as upstream raw material costs rise, with downstream clients maintaining low inventory levels since April 2023, indicating a potential for sustained price increases and profit elasticity [1][10]. - The report emphasizes the importance of the PI3K/AKT/mTOR signaling pathway in cancer treatment, with renewed focus on PI3K inhibitors, particularly following Novartis's acquisition of Synnovation Therapeutics' PI3Kα inhibitor SNV4818 [34][35][36]. Summary by Sections Raw Materials - The report notes that the pharmaceutical raw material sector is poised for price increases due to rising upstream costs and low inventory levels among clients, which could lead to sustained profitability [1][10]. Pharmaceuticals - Novartis announced a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Synnovation Therapeutics' PI3Kα inhibitor SNV4818, indicating a strategic focus on differentiated therapies in the HR+/HER2- breast cancer market [2][34]. Medical Devices - Innovative products in the medical device sector are expanding into international markets, with companies like MicroPort receiving CE certification for pediatric applications of their surgical robots, enhancing their global brand presence [3][11]. Biologics - The report highlights the promising results of the oral GLP-1 Aleniglipron, which showed significant weight loss in clinical trials, suggesting a shift towards oral formulations that improve patient compliance and reduce logistics costs [3][12]. Traditional Chinese Medicine - The report suggests monitoring undervalued high-dividend assets within the traditional Chinese medicine sector as companies begin to release their performance results [3][12]. Healthcare Services and Consumer Healthcare - The report discusses the upcoming release of the DRG/DIP 3.0 version by the National Healthcare Security Administration, expected to be published around July 2023, which will provide insights into the evolving healthcare payment landscape [3][12]. Investment Recommendations - The report recommends focusing on core sectors such as small nucleic acids, bispecific antibodies, and ADCs, while also identifying opportunities during earnings forecast windows and major clinical data release events [2][4].

证券代码：300015 股票简称：爱尔眼科 公告编号：2026-012 爱尔眼科医院集团股份有限公司 关于使用部分自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为提高资金使用效率，合理利用自有资金，获取较好的投资回报，爱尔眼科医 院集团股份有限公司（以下简称"公司"）于 2026 年 3 月 20 日召开第七届董事会 第四次会议，审议通过了《关于使用部分自有资金进行现金管理的议案》，同意公 司在保证日常经营资金需求和资金安全的前提下，使用不超过人民币 15 亿元的部分 自有资金进行现金管理，期限为自公司第七届董事会第四次会议决议之日起 12 个月。在上述额度及期限内，资金可循环滚动使用。公司本次使用部分自有资金进 行现金管理事项在董事会的审批权限内，无需提交公司股东会审议。具体情况如下： 一、投资概况 1、投资目的 为提高资金使用效率，在不影响公司正常经营的情况下，拟使用不超过人民币 15 亿元的部分自有资金进行现金管理，以增加公司投资收益。 4、决议有效期 2、投资品种 公司将按照相关规定严格控制风险，对现金管理产品进行严格评估 ...

爱尔眼科医院集团股份有限公司（以下简称"公司"）第七届董事会第四次 会议于 2026 年 3 月 20 日以通讯表决方式召开，会议通知于 2026 年 3 月 17 日以 邮件方式送达，会议由董事长陈邦先生召集。应到董事 7 人，实到董事 7 人，会 议的召开符合《公司法》和《公司章程》的有关规定，会议合法、有效。经审议， 本次会议一致通过如下议案： 一、《关于部分募投项目结项并将节余募集资金永久补充流动资金的议案》 鉴于公司 2021 年度向特定对象发行股票募投项目中"沈阳爱尔眼视光迁址 扩建项目"已达到预定可使用状态，除预留募集资金 1,216.00 万元用于支付部分 合同尾款及质保金外，公司拟将项目节余募集资金 21,533.68 万元（含利息收入） 全部转入自有账户用于永久补充流动资金，并于募投项目结算完毕后注销相关募 集资金专项账户。公司董事会授权公司财务部门办理本次专户注销事项，相关的 募集资金三方监管协议亦予以终止。 证券代码：300015 股票简称：爱尔眼科 公告编号：2026-010 爱尔眼科医院集团股份有限公司 第七届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、 ...

华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 部分募投项目结项并将节余募集资金 永久补充流动资金的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为爱尔眼科医院集团股份有限公司（以下简称"公司"）向特定对象发行股票 的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》 等有关法律法规和规范性文件的要求，对公司部分募投项目结项并将节余募集资 金永久补充流动资金事项进行了核查，现将核查情况及核查意见发表如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意爱尔眼科医院集团股份有限公司向特 定对象发行股票注册的批复》（证监许可[2022]1704 号）同意注册，公司向特定 对象发行人民币普通股股票（A股）133,467,485 股，每股面值人民币 1.00 元，发 行价格为 26.49 元/股，募集资金总额为人民币 3,535,553,677.65 元，扣除含税的 发行费用人民币 24,311,49 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2026-011 爱尔眼科医院集团股份有限公司 关于部分募投项目结项并将节余募集资金 永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2026 年 3 月 20 日召 开第七届董事会第四次会议，审议通过《关于部分募投项目结项并将节余募集资 金永久补充流动资金的议案》。公司 2021 年度向特定对象发行股票募投项目中 "沈阳爱尔眼视光迁址扩建项目"已达到预定可使用状态，公司拟将该项目节余 资金用于永久补充流动资金。该事项尚需提交股东会审议。现将相关情况公告如 下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意爱尔眼科医院集团股份有限公司向特 定对象发行股票注册的批复》（证监许可[2022]1704 号）同意注册，公司向特定 对象发行人民币普通股股票（A股）133,467,485 股，每股面值人民币 1.00 元， 发行价格为 26.49 元/股，募集资金总额为人民币 3,535,553,677.65 元，扣除含税 的 发 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2026-009 爱尔眼科医院集团股份有限公司 关于2021年限制性股票激励计划暂缓授予部分第四个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次限制性股票解除限售股份上市流通时间为 2026 年 3 月 23 日； 2、本次符合解除限售条件的激励对象共计 3 名，均满足 100%解除限售条件，可解除限 售的限制性股票数量为 198,798 股，占公司目前总股本的 0.0021%。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 9 月 22 日召 开第六届董事会第四十二次会议和第六届监事会第二十七次会议，分别审议通过了 《关于 2021 年限制性股票激励计划暂缓授予部分第四个解除限售期解除限售条件 成就但股票暂不上市的议案》。公司董事会认为暂缓授予部分第四个解除限售期可 解除限售条件已经满足，根据 2020 年年度股东大会对董事会的授权，同意公司按照 《公司 2021 年限制性股票激励计划（草案）》（以下简称"本次激励计划 ...

Group 1: Company Performance and Strategy - The company's market value has returned to 2019 levels, while revenue and net profit have more than doubled compared to seven years ago, indicating significant operational improvement [1] - The company has implemented the "1+8+N" strategy, focusing on establishing one world-class eye hospital and eight national regional eye centers, which are now operational [1] - Future focus will be on high-quality development, enhancing management efficiency, and expanding both domestic and international operations [2] Group 2: Domestic Business Development - The company aims to refine domestic operations through improved management efficiency, medical quality, and service capabilities, supported by a "three-year attack" plan [2] - Approximately 90% of cities at the prefecture level and above are covered by the company's medical network, with some hospitals exceeding 200 million in revenue [3] - There are significant regional disparities in hospital development, influenced by factors such as hospital age, regional economy, and competition, which the company plans to address through collaborative strategies [3] Group 3: International Expansion - The company has established a solid international presence in Europe, Southeast Asia, and North America, with overseas business accounting for about 13% of total revenue [4][5] - Future growth in international markets will be driven by strategic acquisitions and local partnerships, such as the planned acquisition of UK-based Optimax [5] - The company emphasizes a strategy of "top-level design, careful selection, steady expansion, and local operation" to enhance its international operations [5] Group 4: Technological Innovation - The company has partnered with research institutions to explore AI and big data applications in eye disease screening and diagnosis, aiming to upgrade to a platform-based medical institution [4] - The focus will be on integrating new technologies to improve medical service quality and patient experience, while maintaining a rational development approach [4]